Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

SPIRIT IV, 2010 - everolimus ES vs paclitaxel ES

SORT-OUT-3, 2010 - zotarolimus ES vs sirolimus ES

ISAR-DESIRE-2, 2010 - sirolimus ES vs paclitaxel ES

RESOLUTE, 2010 - zotarolimus ES vs everolimus ES

ZEST (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

Thiele, 2009 - sirolimus ES vs MIDCAB

ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol ES vs zotarolimus ES

ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus ES

ENDEAVOR IV, 2009 - zotarolimus ES vs paclitaxel ES

GENIUS-STEMI, 2009 - Genous stent vs bare-metal stent

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

STICH (ventricular reconstruction), 2009 - CABG+surgical ventricular reconstruction vs CABG

ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol ES vs sirolimus ES

COMPARE, 2009 - everolimus ES vs paclitaxel ES

ISAR TEST 3 (BP), 2009 - biodegradable-polymer sirolimus stent vs sirolimus ES

ZEST (vs SES), 2009 - zotarolimus ES vs sirolimus ES

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

BARI 2D, 2009 - CABG or PCI vs medical treatment

DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent

ISAR-TEST-4, 2009 - sirolimus biodegradable polymer vs sirolimus ES

SYNTAX, 2009 - paclitaxel ES vs CABG

ISAR-LEFT-MAIN, 2009 - sirolimus ES vs paclitaxel ES

Kim, 2008 - sirolimus ES vs paclitaxel ES

MISSION, 2008 - sirolimus ES vs bare-metal stent



See also:

  • All coronary artery disease clinical trials
  • All stable angina clinical trials
  • All clinical trials of revascularization with drug eluting stent
  • All clinical trials of zotarolimus ES
    		•  

    ZEST (vs SES) study, 2009

    [NCT00418067]

    Treatments

    Studied treatment zotarolimus-eluting stents
    Control treatment sirolimus-eluting stents
    Concomittant treatment aspirin and clopidogrel prior to the procedure. Aspirin was administered indefinitly and clopidogrel for at least 12 months. Heparin during PCI. Glycoprotein IIb/IIIa inhibitors at discretion

    Patients

    Patients Patients with coronary artery disease
    Exclusion criteria severe left ventricular dysfunction (left ventricular ejection fraction <25%); cardiogenic shock; renal insufficiency; liver dysfunction; left main stenosis; in-stent restenosis of a drug-eluting stent; poor life expectancy
    Baseline characteristics
    age 62y 
    diabetes (%) 30% 
    unstable angina (%) 55% 
    Female (%) 34% 
    bifurcated lesions 15% 
    ostial lesion 7% 
    multi vessels patients 47% 
    No of stent per lesions 1.2 
    No of lesions per patients 1.4 

    Method and design

    Randomized effectives 883 / 878 (studied vs. control)
    Design Parallel groups
    Blinding NA
    Follow-up duration 1 year
    Primary endpoint death, myocardial infarction, TLR


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    6 / 883
         7 / 878
         classic 0,85 [0,29;2,53]

    MI (fatal and non fatal)

    47 / 883
         55 / 878
         0,85 [0,58;1,24]

    MACE

    89 / 883
         73 / 878
         1,21 [0,90;1,63]

    target-vessel revascularization

    89 / 883
         73 / 878
         1,21 [0,90;1,63]

    Stent thrombosis (any, end of follow up)

    4 / 883
         0 / 878
         classic 16,90 [0,30;953,46]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 6 / 883 (0,7%) 7 / 878 (0,8%) 0,85 [0,29;2,53]    
    MI (fatal and non fatal) 47 / 883 (5,3%) 55 / 878 (6,3%) 0,85 [0,58;1,24]    
    MACE 89 / 883 (10,1%) 73 / 878 (8,3%) 1,21 [0,90;1,63]    
    Stent thrombosis (any, end of follow up) 4 / 883 (0,5%) 0 / 878 (0,1%) 7,95 [0,42;150,25]    
    target-vessel revascularization 89 / 883 (10,1%) 73 / 878 (8,3%) 1,21 [0,90;1,63]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 6,80‰ 7,97‰ -1,2‰
    MI (fatal and non fatal) 5,32% 6,26% -9,4‰
    MACE 10,08% 8,31% 1,8%
    target-vessel revascularization 10,08% 8,31% 1,8%


    Reference(s)

    Trials register # NCT00418067
    Study web site link ,

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend